Vivlodex (Oral)
Generic name:meloxicam (oral route) [ mel-OX-i-kam ]
Drug class:Nonsteroidal anti-inflammatory drugs
Medically reviewed by Drugs.com. Last updated on May 3, 2022.
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Meloxicam is contraindicated in the setting of CABG surgery. NSAIDs also cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and those with a prior history of peptic ulcer disease or GI bleeding are at a greater risk for serious GI events .
Commonly used brand name(s)
In the U.S.
- Mobic
- Qmiiz
- Vivlodex
Available Dosage Forms:
- Tablet
- Suspension
- Capsule
- Tablet, Disintegrating
Therapeutic Class: Analgesic
Pharmacologic Class: NSAID
Chemical Class: Oxicam
Uses for Vivlodex
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve the symptoms of arthritis (juvenile rheumatoid arthritis, osteoarthritis, and rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain. However, this medicine does not cure arthritis and will only help you as long as you continue to take it.
This medicine is available only with your doctor's prescription.
Before using Vivlodex
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of meloxicam oral liquid or tablets to treat juvenile rheumatoid arthritis in children 2 years of age and older or meloxicam disintegrating tablets in children 2 years of age and older weighing 60 kilograms (kg) or more.
Appropriate studies have not been performed on the relationship of age to the effects of meloxicam capsules in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of meloxicam in the elderly. However, elderly patients are more likely to have serious stomach, heart, or kidney problems, which may require caution and an adjustment in the dose for patients receiving this medicine.
